Clinical Analysis on Treatment of Chronic Myelomonocytic Leukemia with Allogeneic Hematopoietic Stem Cell Transplantation.
- Author:
Tong WANG
1
;
Wei-Yang LI
1
;
Xiao-Fei QI
1
;
Ri ZHANG
2
;
Zhen-Ming JING
1
;
Hui-Ying QIU
1
;
Yue HAN
1
;
Xiao MA
1
;
Cheng-Cheng FU
1
;
Xiao-Wen TANG
1
;
Su-Ning CHEN
1
;
Ai-Ning SUN
1
;
De-Pei WU
1
Author Information
- Publication Type:Journal Article
- MeSH: Adult; Disease-Free Survival; Female; Graft vs Host Disease; Hematopoietic Stem Cell Transplantation; Humans; Leukemia, Myelomonocytic, Chronic; Male; Retrospective Studies; Siblings; Tissue Donors; Transplantation, Homologous
- From: Journal of Experimental Hematology 2015;23(6):1667-1672
- CountryChina
- Language:Chinese
-
Abstract:
OBJECTIVETo analyze retrospectively the therapeutic efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) for chronic myelomonocytic leukemia (CMML).
METHODSThe engraftment, graft versus host disease (GVHD), infection, relapse, and survival of 13 CMML patients received allo-HSCT were observed. The clinical outcome of allo-HSCT for CMML was analyzed.
RESULTSThirteen (10 males and 3 females) CMML patients with a median age of 38 years old received allo-HSCT including 4 from HLA-matched unrelated donors, 6 from HLA-matched sibling donors and 3 from haploidentical related donors. All 13 patients achieved engraftment, and the median time of neutrophil engraftment and platelet engraftment were 12 (11-18) days and 15 (10-55) days respectively, acute GVHD occurred in 8 patients. After the median follow-up of 13 (6-29) months, the overall survival, disease free survival and relapse were 53.8%, 53.8%, 7.7%, respectively.
CONCLUSIONAllo-HSCT can improve the survival of patients with CMML, and is a effective method for treatment of CMML.
